Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/62390
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vallano Ferraz, Antonio | - |
dc.contributor.author | Fernández Dueñas, Víctor | - |
dc.contributor.author | Pedrós, Consuelo | - |
dc.contributor.author | Arnau de Bolós, Josep M. | - |
dc.contributor.author | Ciruela Alférez, Francisco | - |
dc.date.accessioned | 2015-02-05T09:26:27Z | - |
dc.date.available | 2015-02-05T09:26:27Z | - |
dc.date.issued | 2011-09-01 | - |
dc.identifier.issn | 1871-5273 | - |
dc.identifier.uri | http://hdl.handle.net/2445/62390 | - |
dc.description.abstract | Adenosine receptors are G protein-coupled receptors (GPCRs) that mediate the physiological functions of adenosine. In the central nervous system adenosine A2A receptors (A2ARs) are highly enriched in striatopallidal neurons where they form functional oligomeric complexes with other GPCRs such us the dopamine D2 receptor (D2R). Furthermore, it is assumed that the formation of balanced A2AR/D2R receptor oligomers are essential for correct striatal function as the allosteric receptor-receptor interactions established within the oligomer are needed for properly sensing adenosine and dopamine. Interestingly, A2AR activation reduces the affinity of striatal D2R for dopamine and the blockade of A2AR with specific antagonists facilitates function of the D2R. Thus, it may be postulated that A2AR antagonists are pro-dopaminergic agents. Therefore, A2AR antagonists will potentially reduce the effects associated with dopamine depletion in Parkinson's disease (PD). Accordingly, this class of compounds have recently attracted considerable attention as potential therapeutic agents for PD pharmacotherapy as they have shown potential effectiveness in counteracting motor dysfunctions and also displayed neuroprotective and anti-inflammatory effects in animal models of PD. Overall, we provide here an update of the current state of the art of these A2AR-based approaches that are under clinical study as agents devoted to alleviate PD symptoms | eng |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Bentham Science Publishers | - |
dc.relation.isformatof | Versió postprint del document publicat a: http://dx.doi.org/10.2174/187152711797247803 | - |
dc.relation.ispartof | CNS & Neurological Disorders-Drug Targets, 2011, vol. 10, num. 6, p. 659 -669 | - |
dc.relation.uri | http://dx.doi.org/10.2174/187152711797247803 | - |
dc.rights | (c) Bentham Science Publishers, 2011 | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Malaltia de Parkinson | cat |
dc.subject.classification | Adenosina | cat |
dc.subject.classification | Proteïnes G | cat |
dc.subject.other | Parkinson's disease | eng |
dc.subject.other | Adenosine | eng |
dc.subject.other | G Proteins | eng |
dc.title | An update on adenosine A2A receptors as drug target in Parkinson's disease | eng |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 608447 | - |
dc.date.updated | 2015-02-05T09:26:27Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
608447.pdf | 3.11 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.